JP2022506990A5 - - Google Patents

Info

Publication number
JP2022506990A5
JP2022506990A5 JP2021525169A JP2021525169A JP2022506990A5 JP 2022506990 A5 JP2022506990 A5 JP 2022506990A5 JP 2021525169 A JP2021525169 A JP 2021525169A JP 2021525169 A JP2021525169 A JP 2021525169A JP 2022506990 A5 JP2022506990 A5 JP 2022506990A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
fusion protein
carrier
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021525169A
Other languages
English (en)
Japanese (ja)
Other versions
JP7516369B2 (ja
JP2022506990A (ja
Filing date
Publication date
Priority claimed from PCT/US2019/021474 external-priority patent/WO2019173787A1/en
Priority claimed from PCT/US2019/050708 external-priority patent/WO2020096695A1/en
Application filed filed Critical
Priority claimed from PCT/US2019/060356 external-priority patent/WO2020097394A1/en
Publication of JP2022506990A publication Critical patent/JP2022506990A/ja
Publication of JP2022506990A5 publication Critical patent/JP2022506990A5/ja
Priority to JP2024107251A priority Critical patent/JP2024127939A/ja
Application granted granted Critical
Publication of JP7516369B2 publication Critical patent/JP7516369B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021525169A 2018-11-07 2019-11-07 トランスサイトーシスのための送達構築物および関連する方法 Active JP7516369B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024107251A JP2024127939A (ja) 2018-11-07 2024-07-03 トランスサイトーシスのための送達構築物および関連する方法

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201862756889P 2018-11-07 2018-11-07
US62/756,889 2018-11-07
PCT/US2019/021474 WO2019173787A1 (en) 2018-03-08 2019-03-08 Toxin-derived delivery constructs for oral delivery
USPCT/US2019/021474 2019-03-08
US201962888133P 2019-08-16 2019-08-16
US201962888238P 2019-08-16 2019-08-16
US62/888,133 2019-08-16
US62/888,238 2019-08-16
PCT/US2019/050708 WO2020096695A1 (en) 2018-11-07 2019-09-11 Cholix-derived carriers for oral delivery of heterologous payload
USPCT/US2019/050708 2019-09-11
PCT/US2019/060356 WO2020097394A1 (en) 2018-11-07 2019-11-07 Delivery constructs for transcytosis and related methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024107251A Division JP2024127939A (ja) 2018-11-07 2024-07-03 トランスサイトーシスのための送達構築物および関連する方法

Publications (3)

Publication Number Publication Date
JP2022506990A JP2022506990A (ja) 2022-01-17
JP2022506990A5 true JP2022506990A5 (cg-RX-API-DMAC7.html) 2022-11-01
JP7516369B2 JP7516369B2 (ja) 2024-07-16

Family

ID=70612266

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021525169A Active JP7516369B2 (ja) 2018-11-07 2019-11-07 トランスサイトーシスのための送達構築物および関連する方法
JP2024107251A Pending JP2024127939A (ja) 2018-11-07 2024-07-03 トランスサイトーシスのための送達構築物および関連する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024107251A Pending JP2024127939A (ja) 2018-11-07 2024-07-03 トランスサイトーシスのための送達構築物および関連する方法

Country Status (21)

Country Link
US (4) US20200140511A1 (cg-RX-API-DMAC7.html)
EP (2) EP4083058A3 (cg-RX-API-DMAC7.html)
JP (2) JP7516369B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210110294A (cg-RX-API-DMAC7.html)
CN (1) CN113423722A (cg-RX-API-DMAC7.html)
AU (1) AU2019377117B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021009003A2 (cg-RX-API-DMAC7.html)
CA (1) CA3119060A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021001209A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021007402A2 (cg-RX-API-DMAC7.html)
CY (1) CY1125216T1 (cg-RX-API-DMAC7.html)
DK (1) DK3650037T3 (cg-RX-API-DMAC7.html)
EA (1) EA202191280A1 (cg-RX-API-DMAC7.html)
ES (1) ES2911075T3 (cg-RX-API-DMAC7.html)
IL (1) IL282987B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021005346A (cg-RX-API-DMAC7.html)
PL (1) PL3650037T3 (cg-RX-API-DMAC7.html)
PT (1) PT3650037T (cg-RX-API-DMAC7.html)
SG (1) SG11202104721RA (cg-RX-API-DMAC7.html)
TW (1) TW202031678A (cg-RX-API-DMAC7.html)
WO (1) WO2020097394A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11246915B2 (en) 2010-09-15 2022-02-15 Applied Molecular Transport Inc. Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
PL3762009T3 (pl) 2018-03-08 2022-09-12 Applied Molecular Transport Inc. Pochodzące z toksyny konstrukty dostarczające do dostarczania doustnego
SG11202104734YA (en) 2018-11-07 2021-06-29 Applied Molecular Transport Inc Cholix-derived carriers for oral delivery of heterologous payload
ES2911075T3 (es) 2018-11-07 2022-05-17 Applied Molecular Transport Inc Constructos de administración para transcitosis y métodos relacionados
MX2022001975A (es) 2019-08-16 2022-03-11 Applied Molecular Transport Inc Composiciones, formulaciones y produccion y purificacion de interleucinas.
US20240050559A1 (en) * 2020-06-09 2024-02-15 Icosavax, Inc. Method of making virus-like particle
WO2022177644A1 (en) * 2021-02-16 2022-08-25 Applied Molecular Transport Inc. Methods for treating spondyloarthropathies and related compositions
CN117603361A (zh) * 2022-08-22 2024-02-27 复旦大学附属儿科医院 包含angptl3单抗的融合蛋白

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6022950A (en) 1984-06-07 2000-02-08 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
US5668255A (en) 1984-06-07 1997-09-16 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
ATE66469T1 (de) 1985-01-14 1991-09-15 Neorx Corp Metall-radionuklid markiertes protein fuer diagnose und therapie.
US6051405A (en) 1986-09-24 2000-04-18 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Constructs encoding recombinant antibody-toxin fusion proteins
US4892827A (en) 1986-09-24 1990-01-09 The United States Of America As Represented By The Department Of Health And Human Services Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects
DE60136281D1 (de) * 2000-08-24 2008-12-04 Genentech Inc Methode zur inhibierung von il-22 induziertem pap1
ATE442858T1 (de) 2000-11-27 2009-10-15 Powderject Vaccines Inc Nukleinsäureadjuvantien
US6673574B2 (en) 2000-11-30 2004-01-06 Unigene Laboratories Inc. Oral delivery of peptides using enzyme-cleavable membrane translocators
CA2447795A1 (en) 2001-05-23 2002-11-28 Duotol Ab Suppression of allergic reactions by transdermal administration of allergens in conjunction with or conjugated to toxin subunits or fragments thereof
KR20060022289A (ko) * 2003-06-23 2006-03-09 제네틱스 인스티튜트, 엘엘씨 인터류킨-22 에 대한 항체 및 그의 용도
EP1522585A1 (en) 2003-10-09 2005-04-13 Plant Research International B.V. Chimeric carrier molecules for the production of mucosal vaccines
WO2006135428A2 (en) 2004-10-04 2006-12-21 Trinity Biosystems, Inc. Methods and compositions for inducing an immune response against multiple antigens
US7713737B2 (en) 2004-10-04 2010-05-11 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of macromolecules
US20090148401A1 (en) 2005-12-05 2009-06-11 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of binding partners
EP2046375B1 (en) 2006-07-20 2017-04-05 The General Hospital Corporation Methods and compositions for the selective activation of protoxins through combinatorial targeting
US20090092660A1 (en) 2006-08-09 2009-04-09 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of particles
CA2669094A1 (en) 2006-11-08 2008-05-29 Novavax,Inc. Method of preparing solid dosage forms of multi-phasic pharmaceutical compositions
EP2178559B1 (en) 2007-07-20 2015-06-24 The General Hospital Corporation Recombinant vibrio cholerae exotoxins
CN101361968B (zh) 2007-08-06 2011-08-03 健能隆医药技术(上海)有限公司 白介素-22在治疗脂肪肝中的应用
US20110250199A1 (en) 2008-06-04 2011-10-13 The Government of the United States of America as represented by the Secretary of the Department.... Immunotoxins and uses thereof
AU2009298131B2 (en) 2008-10-02 2016-07-14 Aptevo Research And Development Llc CD86 antagonist multi-target binding proteins
SG176963A1 (en) * 2009-06-22 2012-02-28 Amgen Inc Refolding proteins using a chemically controlled redox state
EP2456470A1 (en) 2009-07-22 2012-05-30 Cenix Bioscience GmbH Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes
WO2011031441A1 (en) 2009-08-28 2011-03-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Therapy with a chimeric molecule and a pro-apoptotic agent
AU2011302645B2 (en) * 2010-09-15 2015-02-26 Applied Molecular Transport, Llc Systems and methods of delivery of bioactive agents using bacterial toxin-derived transport sequences
WO2012101235A1 (en) 2011-01-26 2012-08-02 Cenix Bioscience Gmbh Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes
ES2773115T3 (es) 2011-06-29 2020-07-09 Rani Therapeutics Llc Preparados de agentes terapéuticos para la administración hacia el interior de una luz del tubo intestinal utilizando un dispositivo tragable para la administración de fármacos
PL2970422T3 (pl) 2013-03-15 2018-09-28 F.Hoffmann-La Roche Ag Polipeptydy IL-22 i białka fuzyjne IL-22 Fc i sposoby zastosowania
CN104623637A (zh) 2013-11-07 2015-05-20 健能隆医药技术(上海)有限公司 Il-22二聚体在制备静脉注射药物中的应用
AU2014346554B2 (en) 2013-11-07 2020-06-04 Evive Biotechnology (Shanghai) Ltd Methods of use for IL-22 in the treatment of gastrointestinal graft vs. host disease
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重glp-1/升糖素受體促效劑
JP6641280B2 (ja) 2014-01-09 2020-02-05 サノフイSanofi インスリンアナログおよび/またはインスリン誘導体の安定化された医薬製剤
EP3139965B1 (en) 2014-05-07 2021-09-29 Applied Molecular Transport Inc. Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
AU2015336101A1 (en) 2014-10-22 2017-04-20 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
CN107108712A (zh) * 2014-12-23 2017-08-29 阿尔莫生物科技股份有限公司 提高重组蛋白产量的方法
EP3192805A1 (en) 2016-01-15 2017-07-19 Humanitas Mirasole S.p.A. Inhibitors of t cell activation or stimulation and uses thereof
WO2018005226A2 (en) 2016-06-22 2018-01-04 Alkermes, Inc. Compositions and methods for modulating il-10 immunostimulatory and anti-inflammatory properties
US11523772B2 (en) 2016-12-14 2022-12-13 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with an immunosuppressant
CA3045310A1 (en) 2016-12-14 2018-06-21 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
CA3093386A1 (en) * 2018-03-08 2019-09-12 Applied Molecular Transport Inc. Toxin-derived delivery constructs for oral delivery
SG11202104734YA (en) 2018-11-07 2021-06-29 Applied Molecular Transport Inc Cholix-derived carriers for oral delivery of heterologous payload
ES2911075T3 (es) 2018-11-07 2022-05-17 Applied Molecular Transport Inc Constructos de administración para transcitosis y métodos relacionados

Similar Documents

Publication Publication Date Title
JP2523843B2 (ja) 卵胞刺激ホルモン
JP4585037B2 (ja) アシル化glp−1化合物
US20240238429A1 (en) Delivery constructs for transcytosis and related methods
JP5755398B2 (ja) 伸長されたglp−1化合物
EP3998077B1 (en) Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
Zhao et al. Recombinant production of medium-to large-sized peptides in Escherichia coli using a cleavable self-aggregating tag
JP2018171063A5 (cg-RX-API-DMAC7.html)
CA2634495A1 (en) Process for the production of preformed conjugates of albumin and a therapeutic agent
CN102762591A (zh) 结合il-23的基于纤连蛋白的支架结构域蛋白质
JP2014510518A5 (cg-RX-API-DMAC7.html)
CN107698684A (zh) 包含突变的免疫球蛋白Fc部分的GLP‑1融合蛋白
Ueda et al. Ni (II)-based immobilized metal ion affinity chromatography of recombinant human prolactin from periplasmic Escherichia coli extracts
US10294284B2 (en) Method for preparing C1q recombinant protein
US20190276495A1 (en) Ebola virus vaccine
JP2019518713A5 (cg-RX-API-DMAC7.html)
JP2021506815A5 (cg-RX-API-DMAC7.html)
RU2017104284A (ru) Выделенные полипептиды cd44 и их применение
US11179444B2 (en) Glucagon analogs and methods of use thereof
JP2025514872A5 (cg-RX-API-DMAC7.html)
EA043603B1 (ru) Конструкции для доставки для трансцитоза и связанные способы
RU2023123230A (ru) Мутантный белок f rsv и его применение
RU2021112253A (ru) Вирусоподобные частицы cmv, модифицированные путем слияния
Quagliariello et al. SEQUENCING OF LARGE MEMBRANE PROTEINS: THE Ca-ATPase OF SARCOPLASMIC RETICULUM